The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Application of PET in Breast Cancer

유방암에서 PET의 응용

  • Noh, Dong-Young (Department of Surgery, Seoul National University, College of Medicine Cancer Research Institute, Seoul National University, College of Medicine)
  • 노동영 (서울대학교 의과대학 외과학 교실, 서울대학교 의과대학 암 연구소)
  • Published : 2002.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Positron emission tomography(PET) is an imaging method that employs radionuclide and tomography techniques. Since 1995, we applied PET not only to the diagnosis of breast cancer but also to the detection of abnormalities in the augmented breast and to the detection of metastasis. Until 2001, we evaluated 242 breast cases by PET at PET center of Seoul National University Hospital. Our group has reported serially at the international journals. In the first report, PET showed high sensitivity for detecting breast cancer, both the primary and axillary node metastasis. A total of 27 patients underwent breast operations based on PET results at Seoul National University Hospital from 1995 to 1996. The diagnostic accuracy of PET were 97% for the primary tumor mass and 96% for axillary lymph node metastasis. In case of the breast augmented, PET also showed excellent diagnostic results for primary breast cancer and axillary lymph node metastasis where mammography and ultrasound could not diagnose properly. PET also had outstanding results in the detection of recurrent or metastatic breast cancer(sensitivity 94%, specificity 80%, accuracy 89%). In addition, our study gave some evidence that PET could be applied further to evaluate the growth rate of tumors by measuring SUV, and finally to prognosticated the disease. PET could also be applied to evaluate the response after chemotherapy to measure its metabolic rate and size. In conclsion, PET is a highly sensitive, accurate diagnostic tool for breast cancer of primary lesion in various conditions including metastasis.

Keywords

References

  1. Hoh CK, Hawkins RA, Glaspy JA, Dahlbom M,Tse NY, Hoffman EJ, et a1. Cancer detection withwhole-body PET using 2-esF] fluoro-2-deoxy-Dglucose.J Comp Assit Tomogr 1993;17:582-9.
  2. Wahl RL, Zasadny K, Helvie M, Hutchins GD,Weber B, Cody R. Metabolic monitoring of breastcancer chemohormonotherapy using positronemission tomography: initial evaluation. J ClinOncol 1993;11:2101-11.
  3. Jansson T, Westlin JE, Ahlstrom H, Lilia A,Langstrom B, Bergh J. Positron emissiontomography studies in patients with locallyadvanced and/or metastatic breast cancer: a methodfor early therapy evaluation? J Clin Oncol1995;13:1470-7.
  4. Bruce DM, Evans NTS, Heys SD, Needham G,BenYounes H, Mikecz P, et al. Positron emissiontomography: 2-deoxy-2- [18F]-fluoro-D-g1ucoseuptake in locally advanced breast cancers. Eur JSurg Oncol 1995;21:280-3.
  5. Swets JA. Measuring the accuracy of diagnosis systems. Science 1988;240:1285-93.
  6. Verbeek ALM, Hendriks JH, Holland R. Reductionof breast cancer mortality through mass screeningwith modem mammography. Lancet 1984;1:1222-4.
  7. McGuire AH, Dehdashti F, Siegel BA, Lyss AP,Brodack JW, Marthias CJ, et al. Positrontomographic assessment of 16 a-[18F]-fluoro-17 (3-estradiol uptake in metastatic breast carcinoma. INucl Med 1991;32:1526-31.
  8. Tse NY, Goh CK, Hawkins RA, Zinner MJ,Dahlborn M, Choi Y, et al. The application ofpositron emission tomographic imaging wihfluorodeoxyglucose to the evaluation of breastdisease. Ann Surg 1992;216:27-34.
  9. Neiweg DE, Kim EE, Wong W, Broussard WF,Singletary E, Hortobagyi GN, et al. Positronemission tomography with fluorine-18-deoxyglucosein the detection and staging of breast cancer.Cancer 1993;71:3920-5.
  10. Greco M, Crippa F, Agresti R, Seregni E, GeraliA, Giovanazzi R, et al. Axillary lymph nodestaging in breast cancer by 2-Fluoro-2-Deoxy-DGlucose-Positron Emission Tomography: Clinicalevaluation and alternative management. J Nat!Cancer Inst 2001;93:630-5.
  11. Wahl RL, Helvie MA, Chang AE, Andersson I.Detection of breast cancer in women afteraugmentation mammoplasty using fluorine-18fluorodeoxyglucose-PET. J Nucl Moo 1994;35:872-5.
  12. Noh DY, Yun IJ, Kim JS, Kang HS, Lee DS,Chung JK, et al. Diagnostic value of positronemission tomography for detecting breast cancer.World J Surg 1998;22:223-8.
  13. Silverstein MJ, Handel N, Gamagami P, WaismanJR, Gierson ED, Rasser RJ, et aI. Breast cancer inwomen after augmentation mammoplasty. ArchSurg 1988;123:681-5.
  14. Adler DD, Wahl RL. New methods for imaging thebreast: teclmiques, findings and potential. AIR1995;164:19-30.
  15. Youssefzadeh S, Hittrnair K, Pokieser P, WiesbauerP, Baldt M, Wolf G, et al. Magnetic resonanceimaging of breast implants. Significance comparedto tomography and ultrasonography. Dtsch MedWochenschr 1994;119:1453-7.
  16. Noh DY, Yun IJ, Kang HS, Kim YC, Kim JS,Chung JK, et al. Detection of cancer in augmentedbreast by positron emission tomography. Eur J Surg1999;165:847-51.
  17. Kim TS, Moon WK, Lee DS, Chung IK, Lee MC,Noh DY, et al. Fluorodeoxyglucose positronemission tomography for detection of recurrent ormetastatic breast cancer. World I Surg2001;25:829-34.